Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Thorpe

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Acta Crystallographica. Section F, Structural Biology Communications|May 3, 2019
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndromeJames H Thorpe, Emma V Edgar, Kathrine J Smith, et al.
Thorax|September 30, 2004
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeS G Spiro, R M Rudd, R L Souhami, et al.
Plos Biology|October 21, 2022
Comprehensive characterization of the Hsp70 interactome reveals novel client proteins and interactions mediated by posttranslational modificationsNitika, Bo Zheng, Linhao Ruan, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2019
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitorsAnn L Walker, Alexis Denis, Ryan P Bingham, et al.
Bioorganic & Medicinal Chemistry Letters|December 21, 2019
Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675]Ann L Walker, Alexis Denis, Ryan P Bingham, et al.
The Journal of Investigative Dermatology|March 21, 2021
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton SyndromeJohn Liddle, Veronique Beneton, Matthew Benson, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic CancerPhilip A Harris, Jill M Marinis, John D Lich, et al.
Cancer Cell|October 13, 2020
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Cancer Cell|November 14, 2018
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Journal of Medicinal Chemistry|April 24, 2019
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) KinasePhilip A Harris, Nicolas Faucher, Nicolas George, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Acta Crystallographica. Section F, Structural Biology Communications|May 3, 2019
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndromeJames H Thorpe, Emma V Edgar, Kathrine J Smith, et al.
Thorax|September 30, 2004
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeS G Spiro, R M Rudd, R L Souhami, et al.
Plos Biology|October 21, 2022
Comprehensive characterization of the Hsp70 interactome reveals novel client proteins and interactions mediated by posttranslational modificationsNitika, Bo Zheng, Linhao Ruan, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2019
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitorsAnn L Walker, Alexis Denis, Ryan P Bingham, et al.
Bioorganic & Medicinal Chemistry Letters|December 21, 2019
Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675]Ann L Walker, Alexis Denis, Ryan P Bingham, et al.
The Journal of Investigative Dermatology|March 21, 2021
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton SyndromeJohn Liddle, Veronique Beneton, Matthew Benson, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic CancerPhilip A Harris, Jill M Marinis, John D Lich, et al.
Cancer Cell|October 13, 2020
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Cancer Cell|November 14, 2018
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Journal of Medicinal Chemistry|April 24, 2019
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) KinasePhilip A Harris, Nicolas Faucher, Nicolas George, et al.
Pageof 17